ExPECT: Extraperitoneal End Colostomy Trial

Sponsor
Swansea Bay University Health Board (Other)
Overall Status
Recruiting
CT.gov ID
NCT05163873
Collaborator
Swansea University (Other)
60
3
2
12.7
20
1.6

Study Details

Study Description

Brief Summary

A randomised controlled feasibility study to compare two surgery techniques in the formation of a permanent end colostomy; the trans-peritoneal(TP) technique - currently, the most commonly used technique and the investigational extra-peritoneal(EP) technique, which has been reported in small studies to reduce the risk of parastomal hernia . This feasibility study will primarily aim to determine the feasibility viability of progression to a full multi-centre trial and test study design acceptability for participants. Participants will be asked to consent to be randomised to either the TP or EP procedure during surgery. Following surgery, participants will be followed up to a maximum of 12 months and asked to complete quality of life questionnaires (EQ5D and Colostomy Impact Score). Participant data will also be accessed by research teams at site to collect data on stoma appliance use and complications.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Extra-peritoneal
N/A

Detailed Description

This feasibility study is a multi-centre, single (patient) blinded, randomised controlled trial (RCT). Co-ordination and trial management will be led from Swansea Trials Unit (STU) and we will adhere to their Standard Operating Procedures (SOPs).

The study will take place across 3 sites: Swansea Bay University Health Board (SBUHB); Aneurin Bevan University Health Board and Cardiff and Vale University Health Board. Surgeons at all three sites have experience with both interventional extra-peritoneal surgical technique and the most commonly used transperitoneal technique.

The investigators aim to recruit 60 participants over 12 months. Local recruitment will be co-ordinated by PIs and research teams. Recruitment is aimed to be equally distributed across all sites. Participants will be equally randomised by arm in each of the three sites: to receive the EP colostomy formation (Intervention) or the standard transperitoneal (TP) technique. Participants will remain blinded as to their treatment until the close of the study.

Data collection will be performed by the Welsh Barbers trainee collaborative and the clinical and research teams, with support from PIs. Data will be stored centrally in REDCap (Research Electronic Data Capture) software.

The investigators will explore whether it is possible to establish a research infrastructure in which data can be collected and co-ordinated across sites and for patients to be followed up effectively. The investigators will also look to demonstrate standardisation of the operative technique for EP stoma formation and to determine which outcome measures a future trial should explore. This feasibility trial be evaluated against specific progression criteria.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
ExPECT: Extraperitoneal End Colostomy Trial - Feasibility Phase
Actual Study Start Date :
Dec 9, 2021
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Jan 1, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Trans-peritoneal

Surgery technique in the formation of permanent end colostomy

Experimental: Extra-peritoneal

Surgery technique in the formation of permanent end colostomy

Procedure: Extra-peritoneal
Surgery procedure: a non-mesh prophylactic surgical technique to prevent PH

Outcome Measures

Primary Outcome Measures

  1. Patient-reported EQ5D [1 day (At time of consent)]

    Quality of life measure

  2. Patient-reported EQ5D [Week 6]

    Quality of life measure

  3. Patient-reported EQ5D [Week 26]

    Quality of life measure

  4. Patient-reported EQ5D [Week 52]

    Quality of life measure

  5. Patient-reported Colostomy Impact Score [Week 6]

    Quality of life measure. A scoring system is in place for this measure - 0-9 indicates a minor colostomy impact, 10-38 indicates a major colostomy impact.

  6. Patient-reported Colostomy Impact Score [Week 26]

    Quality of life measure. A scoring system is in place for this measure - 0-9 indicates a minor colostomy impact, 10-38 indicates a major colostomy impact.

  7. Patient-reported Colostomy Impact Score [Week 52]

    Quality of life measure. A scoring system is in place for this measure - 0-9 indicates a minor colostomy impact, 10-38 indicates a major colostomy impact.

  8. Rate of parastomal hernia [Week 6]

    Quantitative frequency of hernia formation

  9. Rate of parastomal hernia [Week 26]

    Quantitative frequency of hernia formation.

  10. Rate of parastomal hernia [Week 52]

    Quantitative frequency of hernia formation

  11. Rate of AE/SAE related to intervention procedure [30 days post-surgery]

    Safety data

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged 18 years and over

  • Able and willing to give informed consent to participate

  • Elective patient for colorectal surgery requiring formation of permanent end colostomy (This may include patients undergoing surgery for rectal or anal cancer, inflammatory bowel disease, diverticular disease and functional bowel disorders)

  • Suitable to receive both trans-peritoneal and extra-peritoneal techniques

Exclusion Criteria:
  • Lacking the capacity to consent

  • Having emergency surgery

  • Previous or current abdominal wall stoma

  • Intention to form loop colostomy, ileostomy or double-barrelled stoma

  • Previous incisional hernia repair with disruption of abdominal wall layers

  • Pregnant or breastfeeding (as determined by standard NHS procedures)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cardiff and Vale University Health Board Cardiff United Kingdom
2 Aneurin Bevan University Health Board Newport United Kingdom
3 Swansea Bay University Health Board Swansea United Kingdom

Sponsors and Collaborators

  • Swansea Bay University Health Board
  • Swansea University

Investigators

  • Study Director: Gregory Taylor, Swansea Bay University Health Board

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Swansea Bay University Health Board
ClinicalTrials.gov Identifier:
NCT05163873
Other Study ID Numbers:
  • 291897
First Posted:
Dec 20, 2021
Last Update Posted:
Feb 23, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Swansea Bay University Health Board
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2022